Coloplast (CPSE:COLO B) Climbed, What Is Behind The Latest Attention?

Coloplast (CPSE:COLO B) is in focus after third quarter earnings, which showed organic revenue and EBIT growth and a reaffirmed full year outlook, despite ongoing reimbursement pressure in the Biologics segment.

See our latest analysis for Coloplast.

At a share price of DKK435.6, Coloplast has seen a 3.0% 1 day share price return and a 5.8% 90 day share price return, while the 5 year total shareholder return is down 54.4%. This suggests that recent momentum has improved compared with a weaker long term record.

If Coloplast's latest moves have you thinking about other healthcare ideas, this could be a good moment to scan for opportunities in 131 healthcare AI stocks.

Coloplast now trades close to analyst targets yet still screens at a large intrinsic discount. After the latest rebound, does fair value sit nearer the market price or closer to those much lower model estimates?

Most Popular Narrative: 5.7% Undervalued

Coloplast's most followed narrative pegs fair value at DKK461.90, slightly above the last close at DKK435.60. This frames the current discount as modest rather than extreme.

The ongoing reorganization into distinct Chronic Care and Acute Care units, with a dedicated R&D function for Chronic Care, is designed to accelerate innovation cycles and improve time-to-market for new products. This is expected to drive higher revenue and operating margins by leveraging user-focused innovation and maximizing manufacturing efficiency.

Read the complete narrative.

Want to see what underpins that fair value for Coloplast? The narrative leans on a specific growth runway, margin reset and a future earnings multiple that may surprise you.

Result: Fair Value of DKK461.90 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Coloplast's story could change quickly if U.S. competitive bidding affects Chronic Care pricing or if further recalls and regulatory setbacks weigh on margins and growth expectations.

Find out about the key risks to this Coloplast narrative.

Another View on Coloplast Valuation

The first narrative pegs Coloplast at DKK461.90, implying the stock is about 5.7% below that fair value. Yet on a simple P/E lens, things look less comfortable. Coloplast trades on 46.6x earnings, compared with a fair ratio of 37.2x and an industry average of 26.4x, as well as a peer average of 37.8x. That premium suggests less room for error if earnings or margins disappoint.

Put differently, the SWS fair ratio points to a level the market could drift toward over time if sentiment cools. This would mean less potential upside than the narrative suggests and more valuation risk if growth expectations ease. Which signal do you want to lean on when you size any position in Coloplast?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Feeling conflicted about Coloplast after all of this? Take a closer look at both sides of the story by starting with the 2 key rewards and 4 important warning signs.

Looking for more investment ideas beyond Coloplast?

If Coloplast has sharpened your focus on quality, do not stop here. Broaden your watchlist now so you are not catching up after the next move.

• Target resilient balance sheets by checking companies in the solid balance sheet and fundamentals stocks screener (435 results) for businesses that pair financial strength with disciplined fundamentals.
• Spot potential value gaps by reviewing the 264 high quality undervalued stocks where quality and pricing conditions may line up more attractively.
• Hunt for future leaders early by scanning the screener containing 609 high quality undiscovered gems before wider attention arrives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com